United States RE40045: What Is Covered, What the Claims Actually Require, and Where It Sits in the US Landscape
What does RE40045 claim in the US?
RE40045’s claim set is directed to fixed-dose combination inhalation products containing:
- Salmeterol (or a physiologically acceptable salt), and
- Fluticasone propionate,
as a combined preparation for simultaneous, sequential, or separate inhalation administration for treatment of respiratory disorders.
The independent concept is broad on the administration pattern (“simultaneous, sequential or separate”) and on formulation format (metered dose inhaler or metered dry powder), while the dependent claims narrow to:
- a specific salmeterol salt identity (1-hydroxy-2-naphthalenecarboxylate), and
- quantitative per-dose ranges (salmeterol and fluticasone per dosage unit).
The claims also include method-of-treatment and method-of-manufacture uses, with twice-daily and daily dose ranges in the method claims.
What are the claim elements, translated into enforceable requirements?
Claim 1 (base composition scope)
A pharmaceutical composition comprising:
1) Effective amounts of:
- salmeterol or a physiologically acceptable salt, and
- fluticasone propionate
2) as a combined preparation
3) for inhalation
4) for treatment of respiratory disorders
5) with administration mode including simultaneous, sequential, or separate administration by inhalation.
Key enforceable breadth points
- “Combined preparation” covers more than co-packaging: the claim language explicitly allows simultaneous, sequential or separate inhalation administration.
- “Respiratory disorders” is an open-ended clinical category unless limited by specification (not provided here).
- “Physiologically acceptable salt” gives salt flexibility in Claim 1, but the salt is later locked down in Claims 2, 5, and 6.
Claim 2 (salt-limited composition scope)
Claim 1, where salmeterol is present as its 1-hydroxy-2-naphthalenecarboxylate salt.
This is a concrete chemical identity requirement. Any design-around that substitutes a different salmeterol salt would fall outside Claims 2/5/6.
Claim 3 (device / product form)
Claim 1 in the form of:
- a metered dose inhaler (MDI) or
- a metered dry powder composition (dry powder inhaler context).
This is narrower than Claim 1’s composition concept and is still product-form restricted.
Claim 4 (per-dose quantitative ranges)
Claim 1 dosage unit containing:
- 25 to 100 μg salmeterol (or its physiologically acceptable salt), and
- 25 to 500 μg fluticasone propionate
per dosage unit.
This is a hard numeric limitation. If either component is outside the stated ranges per unit, Claim 4 is not met.
Claim 5 and 6 (salt + form + dosage ranges)
- Claim 5: Claim 2 in MDI or metered dry powder form.
- Claim 6: Claim 2 dosage unit containing:
- 25 to 100 μg of the 1-hydroxy-2-naphthalenecarboxylate salt of salmeterol, and
- 25 to 500 μg fluticasone propionate per dosage unit.
- Claim 7: Claim 6 in MDI or metered dry powder form.
So the tightest composition claim scope is Claim 6 + Claim 7: specific salt identity + per-dose ranges + specific inhalation device/form factor.
How do the use and method claims expand enforcement?
Claim 8 (manufacture use)
Use of salmeterol (or salt) and fluticasone propionate in the manufacture of pharmaceutical compositions as combined preparations for simultaneous, sequential or separate inhalation administration for treatment of respiratory disorders.
This targets manufacturers who make the composition intended for the specified use.
Claim 9 (method-of-treatment)
Method of treating respiratory disorders by:
- simultaneous, sequential or separate inhalation administration of:
- salmeterol (or salt), and
- fluticasone propionate,
in effective amounts.
This gives enforcement coverage beyond the product itself into actual treatment regimens where the combination is administered in the allowed timing relationship.
Claim 10 (twice daily limitation)
Claim 9 where the administration is twice daily.
This narrows the method to a dosing schedule.
Claim 11 (daily dose ranges)
Claim 10 where:
- salmeterol (or salt): 50 to 200 μg per day
- fluticasone propionate: 50 to 1000 μg per day
This creates a second numeric fence on actual dosing.
What does this imply for claim coverage and design-around?
Administration timing is not a differentiator
Because Claims 1, 8, and 9 all cover:
- simultaneous
- sequential
- separate
by inhalation, an argument that the products are administered at different times is not enough to move out of claim scope, as long as it matches “effective amounts” and “combined preparation” language in composition claims, and as long as the clinician regimen matches in the method claims.
Salt choice is the clearest composition-level pressure point
- Claim 1 is broad on “physiologically acceptable salt,” but
- Claims 2, 5, 6, and 7 specifically lock to 1-hydroxy-2-naphthalenecarboxylate salt.
A competitor using a different salmeterol salt could potentially avoid the tighter claims while still possibly falling under Claim 1 and related manufacture and method claims if “physiologically acceptable salt” is met.
Numeric dose ranges are the clearest manufacturing and product-formulation pressure point
- Per dosage unit: Claims 4 and 6
- salmeterol: 25-100 μg
- fluticasone: 25-500 μg
- Daily regimen: Claim 11
- salmeterol: 50-200 μg per day
- fluticasone: 50-1000 μg per day
Any formulation that changes the labeled delivered microgram per actuation (or per defined dosage unit) risks missing these ranges. Any clinical regimen that changes daily delivered amounts and/or dosing frequency risks missing Claim 10 and 11.
Device-form is a secondary differentiator
Claims 3, 5, and 7 restrict to:
- MDI, or
- metered dry powder
This does not clearly cover nebulized liquid or non-metered inhalation formats if the claims are strictly construed.
What is the practical scope across likely product archetypes?
RE40045’s claims map cleanly to an inhaled fixed-dose dual therapy archetype:
- a metered formulation delivering salmeterol and fluticasone propionate per dose unit, and
- use regimens twice daily with daily doses within the claimed range.
The claims are not tied to a particular respiratory disease subtype (e.g., asthma vs COPD) in the text provided; they require “respiratory disorders.” Enforcement therefore depends on how the patent specification defines the intended disorders and on how courts construe that term in context (not provided here).
Patent landscape positioning in the US (what can be inferred from the claim structure)
Even without the underlying bibliographic record and prosecution history, the claim drafting strongly suggests RE40045 is part of the US secondary intellectual property layer around an inhaled salmeterol + fluticasone propionate combination, with:
- early breadth anchored in a combination inhalation method and composition concept, and
- later narrowing dependent claims around:
- a specific salmeterol salt,
- dose-unit microgram ranges,
- twice-daily dosing and daily dose ranges,
- and inhaler product forms.
In practical landscape terms, investors and R&D teams typically evaluate whether a competitor’s product:
1) uses the same salmeterol salt identity,
2) matches dose-unit delivered microgram ranges,
3) matches twice-daily dosing and daily microgram ranges, and
4) uses an MDI or metered dry powder format for the composition claims.
Where the competitor differs on any one of these, it may still be exposed under broader claims (notably Claim 1 and Claim 9/8), but the probability of reading directly on dependent claims declines sharply.
Claim-by-claim “scope matrix” for infringement-risk triage
| Claim |
Core requirement |
Main constraint type |
Tightest design trigger |
| 1 |
Salmeterol (or acceptable salt) + fluticasone propionate combined inhalation for respiratory disorders; simultaneous/sequential/separate |
Broad composition/use scope |
“Combined preparation” + administration mode |
| 2 |
Claim 1 with specific salt: salmeterol 1-hydroxy-2-naphthalenecarboxylate |
Salt identity |
Using another salmeterol salt |
| 3 |
Claim 1 as MDI or metered dry powder |
Form factor |
Liquid nebulization / non-metered formats |
| 4 |
Claim 1 dosage unit: salmeterol 25-100 μg and fluticasone 25-500 μg |
Numeric per-dose ranges |
Per-actuation microgram outside range |
| 5 |
Claim 2 as MDI or metered dry powder |
Salt + form |
Different inhalation device/form |
| 6 |
Claim 2 dosage unit: salmeterol salt 25-100 μg + fluticasone 25-500 μg |
Salt identity + numeric per-dose ranges |
Different salt and/or microgram range |
| 7 |
Claim 6 as MDI or metered dry powder |
Salt + numeric + form |
Different inhalation device/form |
| 8 |
Manufacturing use for the combined preparation with allowed timing modes |
Use in manufacturing |
Manufacturing intended for the specified combined use |
| 9 |
Method of treating respiratory disorders via allowed timing combined inhalation |
Treatment method |
Timing and “effective amounts” regimen |
| 10 |
Claim 9: twice daily |
Dosing schedule |
Different frequency |
| 11 |
Claim 10: salmeterol 50-200 μg/day, fluticasone 50-1000 μg/day |
Numeric daily ranges |
Daily microgram outside range |
Key Takeaways
- RE40045 claims a salmeterol (any physiologically acceptable salt) + fluticasone propionate inhaled combination for respiratory disorders, with simultaneous, sequential, or separate inhalation administration covered in both composition/use and method claims.
- Salt identity becomes a hard limitation in Claims 2, 5, 6, and 7 via salmeterol 1-hydroxy-2-naphthalenecarboxylate.
- Dose containment is enforced twice: per dosage unit (Claims 4 and 6) and per day (Claim 11), with twice daily required in the method claims (Claim 10).
- Product form matters for the dependent composition claims (Claims 3, 5, 7) through MDI or metered dry powder.
- From an actionable standpoint, infringement triage centers on: salmeterol salt choice, delivered micrograms per actuation / dosage unit, daily dosing regimen, and inhalation format.
FAQs
-
Does RE40045 require the salmeterol and fluticasone to be administered in the same inhalation device at the same time?
No. The claims include simultaneous, sequential or separate inhalation administration modes.
-
Which claims require a specific salmeterol salt?
Claims 2, 5, 6, and 7 require salmeterol as the 1-hydroxy-2-naphthalenecarboxylate salt.
-
What are the per-dosage-unit dose ranges in the composition claims?
Claims 4 and 6: salmeterol 25-100 μg (or the specified salt 25-100 μg) and fluticasone propionate 25-500 μg per dosage unit.
-
What are the daily dose ranges in the method claims?
Claim 11: salmeterol 50-200 μg/day and fluticasone propionate 50-1000 μg/day, with twice-daily dosing required by Claim 10.
-
Do the claims cover both MDIs and dry powder inhalation formats?
Yes, via dependent claims 3, 5, and 7 requiring metered dose inhalers or metered dry powder compositions.
References
[1] United States Patent RE40045 (claim text provided in prompt).
